CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
Ibutilide +1 moredrug
Likely dose
Ibutilide 0.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01014741
NCT01014741N/ACompleted

Modified Stepwise Ablation Guided by Low Dose Ibutilide in Chronic Atrial Fibrillation

Vivek Reddy·interventional·Posted Nov 17, 2009·Updated Feb 14, 2018

In Brief

A clinical study evaluating Ibutilide and Placebo for Persistent Atrial Fibrillation. Completed, enrolled 200 participants across 7 sites in 3 countries.

Detailed Summary

Procedures for ablation of persistent or long lasting atrial fibrillation are frequently long and require extensive ablation. Some electrophysiologists administer the drug ibutilide during these procedures to help organize the fibrillatory activity of the left atrium with the hope that this may shorten the length of the procedure and duration of ablation needed. Currently there is no standardized approach of administering the drug ibutilide during these procedures, thus the investigators cannot be certain that administering this drug does in fact facilitate the procedure. The aim of the MAGIC-AF Trial is to see if administering a standard dose of the drug ibutilide at a standard time in the procedure can allow for a reduction in the ablation procedure time. The investigators hypothesize that administering ibutilide during these procedures will result in a reduction in the procedure and ablation time required.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, South Korea, United States

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 17, 2009
Enrollment StartOct 1, 2009
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 16.6 years ago

Interventions

Ibutilidedrug

0.25mg IV ibutilide after PV isolation prior to CFE ablation

Placebodrug

Placebo after PV isolation prior to CFE ablation.